Madrigal Pharmaceuticals (MDGL) closed at $432.60 on November 10, 2026, unchanged from the previous close, on volume of 436,564 shares (30-day average 454,819).
Data as of November 10, 2026.
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Oct 22, 2026 | 12 Leg Put Combo with Ratio | 18-Dec-26240 : 250[2x] : 260 : 290 : 300[2x] : 310 : 340 : 350[2x] : 360 : 390 : 400[2x] : 410 P | 1,200 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 9, 2026. See the 10 largest for 30, 60 and 90 days
Globe Newswire (Tue, 10-Nov 2:49 PM ET)
These healthcare stocks have tumbled in 2026, yet Quant ratings stay positive
Seeking Alpha News (Tue, 10-Nov 12:38 PM ET)
Madrigal’s Balanced Outlook Supports Hold as Competition Risks Rise; Price Target Unchanged at $479
TipRanks (Tue, 10-Nov 5:26 AM ET)
Newsfile (Tue, 10-Nov 4:35 AM ET)
Globe Newswire (Mon, 9-Nov 1:20 PM ET)
ACCESS Newswire (Mon, 9-Nov 10:25 AM ET)
Newsfile (Mon, 9-Nov 4:20 AM ET)
Business Wire (Sun, 8-Nov 11:38 PM ET)
Globe Newswire (Sat, 7-Nov 11:41 AM ET)
PRNewswire (Fri, 6-Nov 8:07 PM ET)
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
Madrigal Pharmaceuticals trades on the NASDAQ stock market under the symbol MDGL.
As of November 10, 2026, MDGL stock price declined to $432.60 with 436,564 million shares trading.
MDGL has a beta of 0.03, meaning it tends to be less sensitive to market movements. MDGL has a correlation of 0.00 to the broad based SPY ETF.
MDGL has a market cap of $9.99 billion. This is considered a Mid Cap stock.
Last quarter Madrigal Pharmaceuticals reported $431 million in Revenue and $1.83 earnings per share. This beat revenue expectation by $27 million and exceeded earnings estimates by $2.92.
In the last 3 years, MDGL traded as high as $615.00 and as low as $134.90.
The top ETF exchange traded funds that MDGL belongs to (by Net Assets): VTI, VB, XBI, VBK, VXF.
MDGL has underperformed the market in the last year with a return of -11.6%, while the SPY ETF gained +12.9%. In the last 3 month period, MDGL fell short of the market, returning -15.2%, while SPY returned -2.8%. However, in the most recent 2 weeks MDGL has outperformed the stock market by returning -1.2%, while SPY returned -2.0%.
MDGL support price is $419.67 and resistance is $445.91 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MDGL shares will trade within this expected range on the day.
